ImmuCell (NASDAQ:ICCC) Share Price Passes Above Two Hundred Day Moving Average – What’s Next?

ImmuCell Co. (NASDAQ:ICCC)’s stock price passed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $4.44 and traded as high as $4.93. ImmuCell shares last traded at $4.85, with a volume of 12,836 shares traded.

ImmuCell Stock Down 1.8 %

The company has a debt-to-equity ratio of 0.36, a current ratio of 3.11 and a quick ratio of 1.44. The firm has a market capitalization of $43.22 million, a P/E ratio of -9.70 and a beta of 0.62. The firm’s fifty day moving average price is $5.14 and its 200-day moving average price is $4.44.

ImmuCell (NASDAQ:ICCC) last issued its quarterly earnings results on Tuesday, February 25th. The biotechnology company reported $0.06 earnings per share (EPS) for the quarter. ImmuCell had a negative return on equity of 15.32% and a negative net margin of 15.99%. The firm had revenue of $7.75 million during the quarter.

Institutional Investors Weigh In On ImmuCell

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC increased its holdings in shares of ImmuCell by 13.9% in the fourth quarter. Geode Capital Management LLC now owns 64,538 shares of the biotechnology company’s stock valued at $332,000 after buying an additional 7,878 shares in the last quarter. Mesirow Financial Investment Management Inc. grew its holdings in shares of ImmuCell by 100.0% in the 4th quarter. Mesirow Financial Investment Management Inc. now owns 24,356 shares of the biotechnology company’s stock worth $125,000 after acquiring an additional 12,178 shares during the last quarter. Northern Trust Corp grew its holdings in shares of ImmuCell by 51.0% in the 4th quarter. Northern Trust Corp now owns 44,374 shares of the biotechnology company’s stock worth $229,000 after acquiring an additional 14,982 shares during the last quarter. Citadel Advisors LLC acquired a new stake in shares of ImmuCell during the fourth quarter worth $149,000. Finally, Dauntless Investment Group LLC purchased a new stake in shares of ImmuCell during the fourth quarter valued at $676,000. 13.47% of the stock is currently owned by institutional investors.

ImmuCell Company Profile

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.